	US 11,969,461 B2
	Composition comprising botulinum toxin
Klaus Fink, Cologne (DE); Harold Taylor, Frankfurt am Main (DE); Hermann Russ, Altendorf SZ (CH); and Peter Boderke, Schwalbach (DE)
Assigned to MERZ PHARMA GMBH & CO. KGAA, Frankfurt am Main (DE)
Appl. No. 16/079,367
Filed by MERZ PHARMA GMBH & CO. KGAA, Frankfurt am Main (DE)
PCT Filed Feb. 28, 2017, PCT No. PCT/EP2017/054596 § 371(c)(1), (2) Date Aug. 23, 2018, PCT Pub. No. WO2017/148915, PCT Pub. Date Sep. 8, 2017.
Claims priority of application No. 16158302 (EP), filed on Mar. 2, 2016.
Prior Publication US 2019/0060422 A1, Feb. 28, 2019
Int. Cl. A61K 8/64 (2006.01); A61K 8/73 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 38/48 (2006.01); A61K 47/36 (2006.01); A61P 21/00 (2006.01); A61Q 19/08 (2006.01)

CPC A61K 38/4893 (2013.01) [A61K 8/64 (2013.01); A61K 8/735 (2013.01); A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 47/36 (2013.01); A61P 21/00 (2018.01); A61Q 19/08 (2013.01); A61K 2800/91 (2013.01)]

13 Claims

1. A composition comprising consisting of:

a) purified or recombinant botulinum neurotoxin;

b) sterilized saline; and

c) non-crosslinked hyaluronic acid having an average molecular weight of 2.5 MDa to 4.5 MDa and an intrinsic velocity of from 2.7 to 3.3 m³/kg,

wherein said composition is a sterilized composition having a dynamic viscosity from 1.5 to 4 Pa*s when determined at 25° C. using an oscillation frequency of 1 Hz.